Sipuleucel-T for the treatment of prostate cancer

Drugs of Today

Volumn 44, Issue 4, 2008, Pages 271-278

  Harzstark, Andrea L ^a   Small, Eric J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Box 1711 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; KEYHOLE LIMPET HEMOCYANIN; PA 2024; PLACEBO; PROSTATE SPECIFIC ANTIGEN; PROVENGE;

ANTIGEN PRESENTING CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL COUNT; CELL FUNCTION; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DENDRITIC CELL; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; FATIGUE; FEVER; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GLEASON SCORE; HEADACHE; HORMONE SENSITIVITY; HUMAN; IMMUNE RESPONSE; INJECTION SITE REACTION; LEUKAPHERESIS; MALAISE; METASTASIS; MYALGIA; NONHUMAN; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; REVIEW; RIGOR; SEROLOGY; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT;

HUMANS; INFUSIONS, INTRAVENOUS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; TISSUE EXTRACTS;

EID: 46049110918     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2008.44.4.1212301     Document Type: Review

References (24)

1. Steinman, R.M., Witmer-Pack, M., Inaba, K. et al. Dendritic cells: Antigen presentation, accessory function and clinical relevance. Adv Exp Med Biol 1993, 329: 1-9.
2. Almand, B., Resser, J.R., Lindman, B. et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000, 6(5): 1755-66.
3. Gabrilovich, D.I., Corak, J., Ciernik, I.F. et al. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 1997, 3(3): 483-90.
4. Lam, K.W., Li, C.Y., Yam, L.T. et al. Improved immunohistochemical detection of prostatic acid phosphatase by a monoclonal antibody. Prostate 1989, 15(1): 13-21.
5. Solin, T., Kontturi, M., Pohlmann, R. et al. Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): Evaluation by RNA blot analyses. Biochim Biophys Acta 1990, 1048(1): 72-7.
6. Fong, L., Ruegg, C.L., Brockstedt, D. et al. Induction of tissue-specific autoimmne prostatitis with prostatic acid phosphatase immunization: Implications for immunotherapy of prostate cancer. J Immunol 1997, 159(7): 3113-7.
7. Beinart, G., Rini, B.I., Weinberg, V. et al. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer 2005, 4(1): 55-60.
8. Rini, B.I., Weinberg, V., Bok, R. et al. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol 2003, 21(1): 99-105.
9. Lin, A.M., Rini, B.I., Weinberg, V. et al. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int 2006, 98(4): 763-9.
10. Rini, B.I., Weinberg, V., Fong, L. et al. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (Provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 2006, 107(1): 67-74.
11. Beer, T.M., Bernstein, G.T., Corman, J.M. et al. Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC). J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 5059.
12. Small, E.J., Fratesi, P., Reese, D.M. et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000, 18(23): 3894-903.
13. Takaue, Y.T.R., Tobisu, K., Kakizoe, T. et al. Antigen-pulsed dendritic cell therapy for the treatment of hormone-refractry prostate cancer: A phase I trial of APC8015. Proc Am Soc Clin Oncol 2002, 21: Abst 181.
14. Burch P.A., Breen, J.K., Buckner, J.C. et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000, 6(6): 2175-82.
15. Burch, P.A., Croghan, G.A., Gastineau, D.A. et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: A phase 2 trial. Prostate 2004, 60(3): 197-204.
16. Small, E.J., Schellhammer, P.F., Higano, C.S. et al. Placebo- controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006, 24(19): 3089-94.
17. Sipuleucel-T, APC 8015, APC-8015, prostate cancer vaccine - Dendreon. Drugs R D 2006, 7(3): 197-201.
18. Rini, B.I. Technology evaluation: APC-8015, Dendreon. Curr Opin Mol Ther 2002, 4(1): 76-9.
19. Cellular, Tissue and Gene Therapies Advisory Committee Sipuleucel-T Briefing Document. 2007 [cited 2007 June 7]; Available from: www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4291B1_01.pdf.
20. Pound, C.R., Partin, A.W., Eisenberger, M.A. et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA - J Am Med Assoc 1999, 281(17): 1591-7.
21. D'Amico, A.V., Hanks, G.E. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 1993, 72(9): 2638-43.
22. Kudo-Saito, C., Schlom, J., Camphausen, K. et al. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin Cancer Res 2005, 11(12): 4533-44.
23. Mimura, K., Kono, K., Takahashi, A. et al. Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol Immunother 2007, 56(6): 761-70.
24. Roden, A.C., Moser, M.T., Tri, S.D. et al. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol 2004, 173(10): 6098-108.